Skip to main content

Table 2 Incidence and multiplicity of colonic neoplasia.

From: Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands

Group no. Treatment No. of mice Incidence (no. of mice with neoplasms) Multiplicity (no. of tumors/mice, means ± SD)
    Total Adenoma Adeno-carcinoma Total Adenoma Adeno-carcinoma
1 AOM/DSS 10 10/10 (100%) 10/10 (100%) 10/10 (100%) 5.2 ± 3.0 2.1 ± 1.8 3.0 ± 1.8
2 AOM/DSS/0.04% Nimesulide 10 8/10 (80%) 6/10 (60%)a 4/10 (40%)b 1.8 ± 1.7b 1.2 ± 1.3 0.6 ± 1.0c
3 AOM/DSS/0.05% Troglitazone 10 9/10 (90%) 9/10 (90%) 4/10 (40%)b 2.5 ± 1.8a 1.6 ± 1.1 1.2 ± 2.5a
4 AOM/DSS/0.05% Bezafibrate 10 8/10 (80%) 7/10 (70%) 6/10 (60%)a 2.6 ± 2.5a 1.1 ± 1.0a 1.8 ± 2.6
5 0.04% Nimesulide 5 0/5 (0%) 0/5 (0%) 0/5 (0%) 0 0 0
6 0.05% Troglitazone 5 0/5 (0%) 0/5 (0%) 0/5 (0%) 0 0 0
7 0.05% Bezafibrate 5 0/5 (0%) 0/5 (0%) 0/5 (0%) 0 0 0
8 AOM 5 0/5 (0%) 0/5 (0%) 0/5 (0%) 0 0 0
9 DSS 6 0/6 (0%) 0/6 (0%) 0/6 (0%) 0 0 0
10 None 5 0/5 (0%) 0/5 (0%) 0/5 (0%) 0 0 0
  1. a,b,c Significantly different from group 1 by Fisher's exact probability test or Student's t-test (a P < 0.05, b P < 0.01, and c P < 0.005).